Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Luminal A breast cancer resistance mechanisms and emerging treatments, in “Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance”.
Invited editors of Book Series for Elsevier Publications.
The CINs of Polo-Like Kinase 1 in Cancer
Bibliometric analysis of personalized humanized mouse and Drosophila models for effective combinational therapy in cancer patients
Identification of therapeutically relevant targets in telomerase overexpressing prostate cancers
Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer
Congratulations Franco Vizeacoumar (CoI) with PI: Joyce Wilson and CoI: Darryl Falzarano were awarded COVID grant from CIHR
SARS-CoV2 therapeutic discovery through genetic screens and repurposing drugs that target essential virus-host interactions
Riley Plett (Anderson lab) passed her MSc defence on May 4, 2020. Her thesis is titled: "New therapies for CREB3L1-deficient triple negative breast cancer".
Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy
Congratulations Deborah Anderson, Franco Vizeacoumar and Yuliang Wu representing SK in the TFRI – Marathon of Hope Cancer Centres Network Pilot Project in the Prairie Consortium
The Marathon of Hope Cancer Centres Network is a bold vision led by The Terry Fox Research Institute and The Terry Fox Foundation with support from dozens of research and funding p...
New drugs to treat metastatic breast cancer
Targeting MAD1L1 overexpressing breast cancers
Manisha Yadav (Wu lab) passed her MSc defence on Mar 26, 2020. Her thesis is titled: "Structure and function of KH domain in DDX43 and DDX53 cancer antigen helicases".
Chelsea Cunningham (Vizeacoumar lab) passed her PhD defence on Mar 24, 2020. Her thesis is titled: "Synthetic dosage lethal interactions of Polo-like Kinase 1 and their application...